Boryung Corporation (003850.KS)
KRW 10260.0
(-3.39%)
KRW 10260.0
(-3.39%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 204.21 Billion KRW | -1.94% |
| 2022 | 208.24 Billion KRW | -3.37% |
| 2021 | 215.5 Billion KRW | 12.54% |
| 2020 | 191.49 Billion KRW | 93.89% |
| 2019 | 98.76 Billion KRW | 14.69% |
| 2018 | 86.11 Billion KRW | 29.91% |
| 2017 | 66.28 Billion KRW | 159.77% |
| 2016 | 25.51 Billion KRW | -55.48% |
| 2015 | 57.32 Billion KRW | 54.79% |
| 2014 | 37.03 Billion KRW | 16.87% |
| 2013 | 31.68 Billion KRW | -39.33% |
| 2012 | 52.22 Billion KRW | -2.96% |
| 2011 | 53.81 Billion KRW | 126.35% |
| 2010 | 23.77 Billion KRW | 185.1% |
| 2009 | 8.33 Billion KRW | 143.11% |
| 2008 | 3.43 Billion KRW | -77.9% |
| 2007 | 15.51 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 205.8 Billion KRW | 3.86% |
| 2024 Q1 | 198.16 Billion KRW | -2.96% |
| 2023 Q3 | 202.64 Billion KRW | -2.18% |
| 2023 Q2 | 207.16 Billion KRW | -25.26% |
| 2023 FY | 204.21 Billion KRW | -1.94% |
| 2023 Q1 | 277.16 Billion KRW | 33.09% |
| 2023 Q4 | 204.21 Billion KRW | 0.78% |
| 2022 Q2 | 217.66 Billion KRW | 1.8% |
| 2022 FY | 208.24 Billion KRW | -3.37% |
| 2022 Q4 | 208.24 Billion KRW | 0.68% |
| 2022 Q3 | 206.84 Billion KRW | -4.97% |
| 2022 Q1 | 213.81 Billion KRW | -0.78% |
| 2021 Q2 | 186.61 Billion KRW | -1.57% |
| 2021 Q3 | 183.22 Billion KRW | -1.82% |
| 2021 Q4 | 215.5 Billion KRW | 17.62% |
| 2021 FY | 215.5 Billion KRW | 12.54% |
| 2021 Q1 | 189.59 Billion KRW | -0.99% |
| 2020 Q3 | 193.9 Billion KRW | 13.69% |
| 2020 FY | 191.49 Billion KRW | 93.89% |
| 2020 Q4 | 191.49 Billion KRW | -1.24% |
| 2020 Q1 | 92.17 Billion KRW | -6.67% |
| 2020 Q2 | 170.55 Billion KRW | 85.03% |
| 2019 FY | 98.76 Billion KRW | 14.69% |
| 2019 Q4 | 98.76 Billion KRW | 3.42% |
| 2019 Q3 | 95.49 Billion KRW | -4.65% |
| 2019 Q2 | 100.15 Billion KRW | -2.49% |
| 2019 Q1 | 102.7 Billion KRW | 19.27% |
| 2018 Q4 | 86.11 Billion KRW | 17.09% |
| 2018 Q2 | 61.51 Billion KRW | 7.83% |
| 2018 FY | 86.11 Billion KRW | 29.91% |
| 2018 Q1 | 57.05 Billion KRW | -13.94% |
| 2018 Q3 | 73.54 Billion KRW | 19.55% |
| 2017 Q1 | 52.37 Billion KRW | 105.24% |
| 2017 Q2 | 54.35 Billion KRW | 3.78% |
| 2017 Q4 | 66.28 Billion KRW | 30.05% |
| 2017 Q3 | 50.97 Billion KRW | -6.22% |
| 2017 FY | 66.28 Billion KRW | 159.77% |
| 2016 Q4 | 25.51 Billion KRW | 0.0% |
| 2016 FY | 25.51 Billion KRW | -55.48% |
| 2015 Q2 | 35.9 Billion KRW | -6.98% |
| 2015 FY | 57.32 Billion KRW | 54.79% |
| 2015 Q4 | 57.32 Billion KRW | 25.66% |
| 2015 Q3 | 45.61 Billion KRW | 27.03% |
| 2015 Q1 | 38.6 Billion KRW | 4.25% |
| 2014 Q3 | 28.86 Billion KRW | -1.83% |
| 2014 Q4 | 37.03 Billion KRW | 28.31% |
| 2014 FY | 37.03 Billion KRW | 16.87% |
| 2014 Q1 | 27.1 Billion KRW | -14.44% |
| 2014 Q2 | 29.4 Billion KRW | 8.45% |
| 2013 Q3 | 36.6 Billion KRW | 2.0% |
| 2013 Q4 | 31.68 Billion KRW | -13.43% |
| 2013 FY | 31.68 Billion KRW | -39.33% |
| 2013 Q1 | 48.28 Billion KRW | -7.53% |
| 2013 Q2 | 35.88 Billion KRW | -25.68% |
| 2012 Q2 | 49.07 Billion KRW | -7.11% |
| 2012 Q1 | 52.82 Billion KRW | -1.83% |
| 2012 FY | 52.22 Billion KRW | -2.96% |
| 2012 Q4 | 52.22 Billion KRW | -2.69% |
| 2012 Q3 | 53.66 Billion KRW | 9.36% |
| 2011 Q3 | 48.84 Billion KRW | 5.98% |
| 2011 FY | 53.81 Billion KRW | 126.35% |
| 2011 Q1 | 43.17 Billion KRW | 81.63% |
| 2011 Q4 | 53.81 Billion KRW | 10.18% |
| 2011 Q2 | 46.08 Billion KRW | 6.73% |
| 2010 Q1 | 22.65 Billion KRW | 171.69% |
| 2010 FY | 23.77 Billion KRW | 185.1% |
| 2010 Q4 | 23.77 Billion KRW | -6.03% |
| 2010 Q3 | 25.29 Billion KRW | 1.93% |
| 2010 Q2 | 24.81 Billion KRW | 9.55% |
| 2009 Q1 | 10.43 Billion KRW | 204.13% |
| 2009 FY | 8.33 Billion KRW | 143.11% |
| 2009 Q4 | 8.33 Billion KRW | -11.68% |
| 2009 Q3 | 9.44 Billion KRW | 13.75% |
| 2009 Q2 | 8.3 Billion KRW | -20.43% |
| 2008 Q2 | 3.99 Billion KRW | -68.7% |
| 2008 Q4 | 3.43 Billion KRW | -42.18% |
| 2008 Q3 | 5.93 Billion KRW | 48.68% |
| 2008 FY | 3.43 Billion KRW | -77.9% |
| 2008 Q1 | 12.74 Billion KRW | -17.85% |
| 2007 FY | 15.51 Billion KRW | 0.0% |
| 2007 Q1 | 22.87 Billion KRW | 0.0% |
| 2007 Q3 | 15.59 Billion KRW | -1.78% |
| 2007 Q4 | 15.51 Billion KRW | -0.51% |
| 2007 Q2 | 15.88 Billion KRW | -30.59% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -418.22% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 70.484% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 46.549% |
| HANDOK Inc. | 300.01 Billion KRW | 31.931% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -566.021% |
| Yuhan Corporation | 230.07 Billion KRW | 11.238% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 49.788% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -34193.986% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 64.352% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -15724.184% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -139.803% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -371.926% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -125.697% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -669.665% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -418.22% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -85659.557% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 9.259% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | -12.828% |
| JW Holdings Corporation | 554.58 Billion KRW | 63.177% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 6.255% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 7.075% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -19.929% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -342.491% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -420.893% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | -16.111% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -140.351% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -418.22% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 13.336% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 56.521% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -19.929% |
| Yuhan Corporation | 230.07 Billion KRW | 11.238% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | -18.023% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -205.337% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 56.351% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -19.929% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -72.133% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -406.249% |
| CKD Bio Corp. | 146.92 Billion KRW | -38.992% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -39.826% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -323.198% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -32211.322% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -342.491% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 56.367% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -157.241% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -139.803% |
| JW Lifescience Corporation | 46.31 Billion KRW | -340.949% |